Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAM | P19021 | 2/20 | 0.74 |
| ▸ | DGKA | P23743 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 4/20 | 0.56 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.53 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.53 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.53 |
| ▸ | PRKCA | P17252 | 1/20 | 0.51 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.51 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.51 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.51 |
| ▸ | CES2 | O00748 | 3/20 | 0.50 |
| ▸ | CES1 | P23141 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8041026 | 1.00 | PAM (0.74) | PAMDGKATSHRMAPTLMNA | |
| SCHEMBL19940077 | 1.00 | PAM (0.74) | PAMDGKATSHRMAPTLMNA | |
| SCHEMBL3924509 | 1.00 | PAM (0.74) | PAMDGKATSHRMAPTLMNA | |
| SCHEMBL19944379 | 1.00 | PAM (0.74) | PAMDGKATSHRMAPTLMNA | |
| SCHEMBL1901901 | 1.00 | PAM (0.74) | PAMDGKATSHRMAPTLMNA | |
| SCHEMBL17237693 | 1.00 | PAM (0.74) | PAMDGKATSHRMAPTLMNA | |
| SCHEMBL19912168 | 0.94 | PAM (0.71) | PAMDGKATSHRMAPTLMNA | |
| SCHEMBL22077717 | 0.92 | DGKA (0.71) | PAMDGKATSHRMAPTLMNA | |
| SCHEMBL22078522 | 0.92 | DGKA (0.71) | PAMDGKATSHRMAPTLMNA | |
| SCHEMBL9912287 | 0.92 | PAM (0.65) | PAMDGKATSHRMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240391870-A1 | IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY | ARCTURUS THERAPEUTICS, INC. | 2024-11-28 | — | — | US | disclosed |
| EP-4430026-A1 | IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY | Arcturus Therapeutics, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| US-11903992-B2 | Composition comprising lidocaine, l-carnosine and dexpanthenol | CELLIX BIO PRIVATE LIMITED (IN) | 2024-02-20 | — | — | US | disclosed |
| WO-2023187664-A1 | A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF IMMUNE SYSTEM MEDIATED DISEASES | AVACA PHARMA PRIVATE LIMITED (IN) | 2023-10-05 | — | — | WO | disclosed |
| US-20230295081-A1 | IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY | ARCTURUS THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295081-A1 | IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY | ARCTURUS THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295081-A1 | IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY | ARCTURUS THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| EP-4230619-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | CELLIX BIO PRIVATE LIMITED (IN) | 2023-08-23 | — | — | EP | disclosed |
| WO-2023086514-A1 | IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY | ARCTURUS THERAPEUTICS, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| WO-2023086514-A1 | IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY | ARCTURUS THERAPEUTICS, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| EP-3538079-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ORAL INFECTIOUS DISEASES | CELLIX BIO PRIVATE LIMITED (IN) | 2019-09-18 | — | — | EP | disclosed |
| WO-2018122626-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CHRONIC PAIN | CELLIX BIO PRIVATE LIMITED (IN) | 2018-07-05 | — | — | WO | disclosed |
| WO-2018096405-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ORAL INFECTIOUS DISEASES | CELLIX BIO PRIVATE LIMITED (IN) | 2018-05-31 | — | — | WO | disclosed |
| WO-2018096497-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | CELLIX BIO PRIVATE LIMITED (IN) | 2018-05-31 | — | — | WO | disclosed |
| US-8236854-B2 | Lipid-improving agent and composition containing lipid-improving agent | SUNTORY HOLDINGS LIMITED (JP) | 2012-08-07 | — | — | US | disclosed |
| US-20100190857-A1 | LIPID-IMPROVING AGENT AND COMPOSITION CONTAINING LIPID-IMPROVING AGENT | SUNTORY HOLDINGS LIMITED (JP) | 2010-07-29 | — | — | US | disclosed |
| US-7723386-B2 | Lipid-improving agent and composition containing lipid-improving agent | SUNTORY HOLDINGS LIMITED (JP) | 2010-05-25 | — | — | US | disclosed |
| US-20060217441-A1 | Lipid-improving agent and composition containing lipid-improving agent | SUNTORY LIMITED (JP) | 2006-09-28 | — | — | US | disclosed |
| EP-1605768-A2 | LIPID-IMPROVING AGENT AND COMPOSITION CONTAINING LIPID-IMPROVIMG AGENT | SUNTORY LIMITED (JP) | 2005-12-21 | — | — | EP | disclosed |
| WO-2004085582-A2 | LIPID-IMPROVING AGENT AND COMPOSITION CONTAINING LIPID-IMPROVING AGENT | SUNTORY LIMITED (JP) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240391870-A1 | IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY | NSUN3, POLRMT, NPC1L1 | PAM 3398/4885DGKA 807/4885TSHR 1676/4885 |
| US-20230295081-A1 | IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY | NSUN3, POLRMT, NPC1L1 | PAM 3398/4885DGKA 807/4885TSHR 1676/4885 |
| US-11903992-B2 | Composition comprising lidocaine, l-carnosine and dexpanthenol | VNN1, LPL, HMGB1 | PAM 1070/4885DGKA 1522/4885TSHR 4877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.